CardioDx Focused on CAD Test Adoption, Not IPO

The company recently raised more than $40 million, bringing the total since its founding to more than $100 million. Its CEO said, however, that neither an IPO nor an acquisition is in CardioDx's immediate future.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories